The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
about
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
The addition of vildagliptin t ...... randomized, open-label study.
@ast
The addition of vildagliptin t ...... randomized, open-label study.
@en
type
label
The addition of vildagliptin t ...... randomized, open-label study.
@ast
The addition of vildagliptin t ...... randomized, open-label study.
@en
prefLabel
The addition of vildagliptin t ...... randomized, open-label study.
@ast
The addition of vildagliptin t ...... randomized, open-label study.
@en
P2093
P2860
P1476
The addition of vildagliptin t ...... randomized, open-label study.
@en
P2093
Alexander Tenenbaum
Arwa Younis
Dana Eskenazi
Enrique Z Fisman
Ilan Goldenberg
Jonathan Leor
Nili Naftali-Shani
Robert Klempfner
Ronen Goldkorn
P2860
P2888
P356
10.1186/S12933-017-0551-5
P407
P577
2017-05-22T00:00:00Z
P6179
1085558677